← Leaderboards
Jeffrey Crawford
Duke University
$685,042
Attributed
$685,042
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$685,042 · 1
By mechanism
M01$685,042 · 1
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- Herbert Kim Lyerly$48,598,090
- Mark N Feinglos$8,642,419
- John H Sampson$43,413,436
- Michael Barry Kastan$65,974,699
- Eugene W. St Clair$30,992,512
Others in their field
Top investigators on “Antineoplastics”
- David Heimbrook · Leidos Biomedical Research, Inc.$245,744,647
- Leonard Freedman · Leidos Biomedical Research, Inc.$243,278,693
- Charles A Coltman · Southwest Oncology Group$134,454,243
- Gregory H Reaman · National Childhood Cancer Foundation$112,139,479
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,166,869
- Richard L Schilsky · University Of Chicago$90,728,118
Research focus
AntineoplasticsClinical ResearchClinical Trial Phase IDrug Adverse EffectDrug Screening /EvaluationHuman SubjectHuman Therapy EvaluationNeoplasm /Cancer ChemotherapyNonsmall Cell Lung CancerPharmacokinetics
Grant awards (5)
FILGRASTIM SD/01 IN NONSMALL CELL LUNG CANCER$117,022
M01 · FY2002 · RR
FILGRASTIM SD/01 IN NONSMALL CELL LUNG CANCER$293,069
M01 · FY2001 · RR
FILGRASTIM SD/01 IN NONSMALL CELL LUNG CANCER$117,022
M01 · FY2001 · RR
FILGRASTIM SD/01 IN NONSMALL CELL LUNG CANCER$117,022
M01 · FY2001 · RR
FILGRASTIM SD/01 IN NONSMALL CELL LUNG CANCER$40,907
M01 · FY2000 · RR